Nucleic Acids Research Advance Access originally published online on October 24, 2007
Nucleic Acids Research 2007 35(21):7267-7278; doi:10.1093/nar/gkm738
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nucleic Acids Research, 2007, Vol. 35, No. 21 7267-7278
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Molecular Biology |
Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres
1Section of Oncology, Department of Medicine, Haukeland University Hospital, 2Section of Anatomy and Cell Biology, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway, 3Department of Biochemistry, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA and 4NorLux, Neuro-Oncology, Centre Recherche Public Santé, Luxembourg
*To whom correspondence should be addressed. Tel: +47 55586455; Fax: +47 55586360; Email: stig.boe{at}vir.uib.no
Received May 27, 2007. Revised August 24, 2007. Accepted September 5, 2007.
The activation of a telomere maintenance mechanism is required for cancer development in humans. While most tumors achieve this by expressing the enzyme telomerase, a fraction (5–15%) employs a recombination-based mechanism termed alternative lengthening of telomeres (ALT). Here we show that loss of the single-stranded DNA-binding protein replication protein A (RPA) in human ALT cells, but not in telomerase-positive cells, causes increased exposure of single-stranded G-rich telomeric DNA, cell cycle arrest in G2/M phase, accumulation of single-stranded telomeric DNA within ALT-associated PML bodies (APBs), and formation of telomeric aggregates at the ends of metaphase chromosomes. This study demonstrates differences between ALT cells and telomerase-positive cells in the requirement for RPA in telomere processing and implicates the ALT mechanism in tumor cells as a possible therapeutic target.